ArticleNPJ precision oncology2026
Noninvasive prediction of occult pT3a upstaging in localized ccRCC with radiogenomic insights and prognostic relevance.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CT-Based Peritumoral and Perirenal Fat Radiomics in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Grade, Stage, and Adherent Perinephric Fat Prediction.Journal of clinical medicine · 2026Review
- Machine learning-derived mast cell-associated angiogenesis features can serve as prognostic targets for clear cell renal cell carcinoma.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Occult pathological T3a (pT3a) upstaging in cT1b-T2a clear cell renal cell carcinoma (ccRCC) correlated with poor prognosis and necessitated modifications in surgical planning. However, predicting it preoperatively remains challenging. In this multicenter study involving 1661 patients across five institutions and the KiTS23 dataset, RENALNet, a 3D deep learning framework trained on nephrographic-phase CT, was developed and validated. RENALNet outperformed radiomics models, further enhancing diagnostic accuracy when combined with radiologists of varying experience. Grad-CAM visualizations concentrated on anatomically significant invasion sites, improving interpretability. Risk scores derived from RENALNet were found to correlate with Ki-67 proliferation indices and effectively stratified 5-year progression-free survival, demonstrating both biological and prognostic relevance. Transcriptomic analysis revealed that high RENALNet risk was associated with gene expression signatures enriched in pathways such as epithelial-mesenchymal transition, IL6-JAK-STAT3 signaling, and PI3K-Akt signaling, highlighting its link to tumor aggressiveness. RENALNet thus offers a biologically interpretable framework for risk stratification in ccRCC, supporting surgical decision-making and advancing the integration of radiogenomic deep learning into precision oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.